English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 18 April 2019, 20:00 HKT/SGT
Share:
    

Source: ReShape Lifesciences Inc.
ReShape Lifesciences Announces Distribution in Australia

SAN CLEMENTE, CA & MELBOURNE, AU, Apr 18, 2019 - (ACN Newswire) - ReShape Lifesciences™, a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announces that as of April 1, 2019, the company was selling its LAP-BAND® product in the Australian market through a relationship with Satori Healthcare. Satori Healthcare is a medical device distributor focused on the Australian bariatric market.

The founder of Satori Healthcare has over 20 years of experience in the medical device industry, including 6 years of direct responsibility for LAP-BAND while it was owned by Allergan and Apollo Endosurgery respectively. Concurrent with this relationship, ReShape Lifesciences has fully taken over all distribution of the LAP-BAND product in Australia from Apollo Endosurgery, Inc. and will subsequently be recognizing revenue from sales of the product in Australia.

Over 120,000 LAP-BAND procedures have taken place in Australia since the product was launched in the country, making Australia one of the largest worldwide markets for LAP-BAND outside of the U.S. Australia was one of the early adopters of the LAP-BAND technology and has produced some of the strongest data and research on the product. According to the OECD 2017 Obesity Update, based on self-reported data, 27.9% of the Australian adult population are obese, the fifth highest obesity rate of any developed country.

About ReShape Lifesciences Inc

ReShape Lifesciences™ (OTCQB: RSLS) is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved LAP-BAND® Adjustable Gastric Banding System is designed to provide minimally invasive long-term treatment of severe obesity and is an alternative to more invasive surgical stapling procedures such as gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

Investor Contact:
Scott Youngstrom
Chief Financial Officer
ReShape Lifesciences Inc.
+1-949-429-6680 x106
syoungstrom@reshapelifesci.com

SOURCE: ReShape Lifesciences Inc.

Topic: Press release summary
Source: ReShape Lifesciences Inc.

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
UREEQA Announces New Qards Campaign, Staking Pools and Tier Structure  
Sept 16, 2021 21:00 HKT/SGT
Honda Exhibits the World Premiere of All-new BF150, BF135 and BF115 Large-size Marine Outboard Engines at the Genoa International Boat Show 2021  
Sept 16, 2021 18:08 HKT/SGT
Huisen and Xiaomi Formed A Strategic Cooperation to Develop Smart Home Business  
Sept 16, 2021 15:16 HKT/SGT
Applus+ IDIADA and MHI Group to Develop Testing and Verification System for Highly Automated Vehicles  
Sept 16, 2021 13:52 HKT/SGT
Hatten Land Enters into MOU with Singapore Myanmar Investco to Undertake 'Green' Crypto Mining Activities in Melaka  
Sept 16, 2021 08:45 HKT/SGT
AppSealing Introduces Data Encryption Solution for Android Apps  
Sept 16, 2021 08:00 HKT/SGT
AppSealing Introduces Data Encryption Solution for Android Apps  
Sept 16, 2021 08:00 HKT/SGT
Copying the small structures of Salvinia leaves  
Sept 16, 2021 06:00 HKT/SGT
ICCPP Holds GENE TREE Online Roundtable  
Sept 16, 2021 03:00 HKT/SGT
RCEP Qingdao Design Festival opens September 17  
Sept 16, 2021 02:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575